DiagnoCure  In November 2003, Gen-Probe signed a license and collaboration agreement with DiagnoCure under which the companies are developing, and Gen-Probe will market, an innovative urine test to detect a new, highly specific genetic marker for prostate cancer called PCA3.

Corixa Corporation  In January 2005, Gen-Probe signed an agreement with Corixa to license rights to develop molecular diagnostic tests for approximately 50 potential genetic markers in the areas of prostate, ovarian, cervical, kidney, lung and colon cancer.

AdnaGen  In January 2005, Gen-Probe signed an agreement with AdnaGen, a private company based in Germany, to license AdnaGen's innovative "immunocapture" technology. The technology may help increase the accuracy of molecular diagnostic tests to detect prostate and other cancers, help determine the aggressiveness of these malignancies, and monitor responses to therapy.

bioMerieux, Inc.  In September 2004, Gen-Probe entered into non-exclusive licensing agreements with bioMérieux and its affiliates that provide bioMérieux options to access our ribosomal RNA technologies to develop diagnostic products for certain disease targets.

Roche  In February 2005, Gen-Probe signed a supply and purchase agreement with F. Hoffmann-La Roche Ltd. and its affiliate Roche Molecular Systems, Inc. under which Gen-Probe will purchase products for use in molecular diagnostic assays for human papillomavirus (HPV).

Qualigen, Inc.  In November 2004, Gen-Probe acquired from Qualigen an exclusive option to develop a point-of-use nucleic acid testing (NAT) instrument based on Qualigen's FDA-approved FastPack® immunoassay system.

Tosoh Corporation  In December 2003, Gen-Probe entered into agreements with Tosoh Corporation to cross-license intellectual property covering certain NAT technologies. The licenses cover products in clinical diagnostics and other related fields.

Rebio Gen, Inc.  In July 2001, Gen-Probe entered into a license agreement with Chugai Diagnostics Science Co., Ltd., which was later acquired by Fujirebio and re-named Rebio Gen, Inc. The agreement offers a non-exclusive license for Japan in the field of human clinical diagnostics to various of our proprietary technologies.